All In Biotech

Drug Trial Radar · NCT00619359

Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Cisplatin Chemotherapy

Last checked: Nov 19, 2026Latest source record: Mar 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,322 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,322

Actual

Start

Feb 2008

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 21, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.

Conditions

  • Chemotherapy-Induced Nausea and Vomiting (CINV)

Interventions

  • Comparator: fosaprepitant dimeglumineDrug

    single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.

  • Comparator: AprepitantDrug

    Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).

  • DexamethasoneDrug

    Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.

  • DexamethasoneDrug

    Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.

  • OndansetronDrug

    single IV dose of 32 mg of ondansetron on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).Time frame: Overall (in the 120 hours following initiation of cisplatin chemotherapy).

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.